ArticleNature communications2025
Supramolecular chirality largely modulates chemical doping of conjugated polymers.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Solvent-Guided Chiral Assemblies and Chemical Doping of OEG-Functionalized Conjugated Polymers.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Flanking-Group Engineering Unlocks Emerging Functionalities in Diketopyrrolopyrrole Semiconductors.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- New-Era Polymer Thermoelectrics: Material Innovations, Doping Frontiers, Decoupling Strategies, and Unconventional Applications.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Data-Driven Discovery and Experimental Validation of Solvent Polarity Effects on Conjugated Polymer Solution-to-Film Assembly Pathways.Chemistry of materials : a publication of the American Chemical Society · 2026Article
- Non-reciprocal linearly polarized light in simple media.Nature materials · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
Chemical doping has unlocked the touted potential of conjugated polymers by significantly boosting their conductivity and device performance. Yet, the relationship between doping and the polymers' complex, multiscale morphology remains elusive. Herein, we report a surprising find that supramolecular chirality, which up to now had not been considered a parameter relevant to doping, significantly boosts the underpinning redox reaction in conjugated polymer thin films. The chiral helical structures arise during an evaporative assembly process upon meniscus-guided coating, when the originally racemic conjugated polymer chains aggregate first and assemble into chiral twist-bent nematic mesophases which "imprint" their solution-state structure into solid thin films. By manipulating the solution aggregate structures through only subtle variations in the solvent nature, we modulate the structures of the liquid crystal phases to access a broad spectrum of supramolecular chirality, from achiral, to weakly chiral, and to strongly chiral. The differential solubilities of the side-chains and backbones in various solvent environments-elucidated by molecular dynamics simulations-underpin transitions in solution assembly behaviors. Upon sequential doping, the strongly chiral film exhibits a markedly higher charge carrier concentration leading to the highest doping efficiency and electrical conductivity, followed by the weakly chiral and the achiral films. Such increased conductivity in chiral structures is observed across three sets of polymer systems. We further suggest that enhanced crystallinity from chiral assembly facilitates the doping process, while chirality-induced spin selectivity may accelerate oxidation over reduction, together resulting in increased doping efficiency in chiral structures.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.